BioCryst Pharmaceuticals (NASDAQ:BCRX) Issues Quarterly Earnings Results, Meets Expectations

BioCryst Pharmaceuticals (NASDAQ:BCRX) issued its quarterly earnings results on Monday. The biotechnology company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07), Briefing.com reports. The company had revenue of $117.10 million during the quarter, compared to analysts’ expectations of $113.99 million. BioCryst Pharmaceuticals’s revenue was up 35.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.19) EPS.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX remained flat at $7.73 during mid-day trading on Thursday. 560,573 shares of the company were exchanged, compared to its average volume of 2,970,595. BioCryst Pharmaceuticals has a 12-month low of $4.03 and a 12-month high of $8.88. The company has a 50-day moving average of $7.80 and a two-hundred day moving average of $6.98. The stock has a market capitalization of $1.60 billion, a price-to-earnings ratio of -12.67 and a beta of 1.89.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on BCRX shares. Needham & Company LLC reaffirmed a “buy” rating and set a $14.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday. Barclays upped their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday. StockNews.com raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, August 6th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $14.67.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.